Pharmacological and clinical evaluation of lymphocyte function-associated antigen-1 inhibitor, lifitegrast ophthalmic solution
LIU Yuan
SHI Ai-xin
Abstract：Lifitegrast is a nonsteroial anti-inflammatory small molecule antagonist of the integrin lymphocyte function-associated antigen-1 (FDA-1),which mimics the binding epitope of ICAM-1,inhibits the interaction of LFA-1 and ICAM-1,and is indicated for the anti-inflammatory treatment of dry eye disease.In July 2016,lifitegrast was approved by the US FDA for improvement of both sign and symptom of dry eye disease.Clinical trials showed that the drug was safe and well tolerated.The main adverse reactions were instillation site irritation,dysgeusia and reduced visual acuity.In this article,the pharmacology,pharmacokinetics,clinical research and adverse reactions of lifitegrast ophthalmic solution were reviewed.
Keywords：lymphocyte function-associated antigen-1 inhibitordry eye diseaselifitegrast
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 1105-1109 )